C4 Therapeutics (CCCC) Well Positioned With Cemsidomide Trial Data
C4 Therapeutics Inc. (NASDAQ:CCCC) is one of the 11 most popular AI penny stocks to buy now. On February 23, Brookline increased the firm’s price target on C4 Therapeutics Inc. (NASDAQ:CCCC) from $20 to $30, while maintaining its Buy rating on the stock. The price target increase reflects growing conviction following the initiation timing of the Phase 2 cemsidomide/CFT6455 MOMENTUM trial.
Data continues to show cemsidomide’s differentiated safety and tolerability profile, supporting a clear development path for second-line and later patient populations. The firm also noted that the progress further supports expectations for the Phase 1b trial of cemsidomide in combination with elranatamab to begin in the second quarter.
On February 23, C4 Therapeutics Inc. (NASDAQ:CCCC) reported that the first patient had been dosed in the Phase 2 MOMENTUM trial evaluating cemsidomide in combination with dexamethasone for the treatment of relapsed or refractory multiple myeloma. The trial builds on the compelling anti-myeloma activity and differentiated safety profile previously observed in the Phase 1 study.
The company noted that initiating the MOMENTUM trial represents an important milestone in advancing cemsidomide as a potential foundational therapy for multiple myeloma patients seeking a safe, oral, and convenient treatment option.
C4 Therapeutics Inc. (NASDAQ:CCCC) is a clinical-stage biopharmaceutical company that is involved in developing novel targeted protein degradation (TPD) therapies. These small-molecule degrader therapies help to cure cancer, multiple myeloma, and other fatal diseases. The company has established several strategic partnerships, including Merck KGaA, Biogen, and Betta Pharmaceuticals.
While we acknowledge the potential of CCCC as an investment, we believe certain AI stocks offer greater upside potential and carry less downside risk. If you’re looking for an extremely undervalued AI stock that also stands to benefit significantly from Trump-era tariffs and the onshoring trend, see our free report on the best short-term AI stock.
Disclosure: None.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Nifty 50 Is Still Down 4.91% in 2026, So Why Does Citi See 13% Upside?
US Dollar Index: Fed path and CPI focus – Deutsche Bank
VIPMidterm Elections Conclude, Anthropic Initiates IPO
1. Cross-asset performance diverged this week. Between the October 30 and November 6 closes, the S&P 500 fell 2.68%, the Nasdaq 100 dropped 4.91%, and BTC lost 1.88%. Gold and silver rose 4.51% and 5.79%, respectively, while the Hang Seng gained 5.10%. Sharp declines in crude oil and some Asian equity indexes showed how differently assets responded to growth, policy, and event risks. 2. Democrats won majorities in both chambers of Congress in the US midterm elections, and markets rallied before reversing. We focus on actual changes in fiscal negotiations, key committee arrangements, and local industrial policy, especially data-center approvals, energy costs, and the pace of capital expenditure. We do not map party outcomes directly to asset direction. 3. The pullback in technology stocks has put returns on AI investment under renewed scrutiny. Whether rapid growth can cover financing, construction, and ongoing compute costs is becoming a key valuation test. For related positions, monitor policy implementation, customer capital expenditure, and cash collection together, and do not read a one-day rebound as a sign that the pressure has passed. 4. Anthropic's IPO preparations are putting the growth quality, operating profitability, and funding needs of AI model companies under public-market scrutiny. Valuations discussed for the offering are not final pricing, and participating in related products also requires assessing fees, allocation methods, asset rights, and trading restrictions. Assets in focus: BTC, the Nasdaq 100, crude oil, and gold, along with key earnings from companies including CSCO, AMAT, and CEG
Asian Stocks Rebound, Nikkei Up 3.4%, but Can They Lead Wall Street?
Crypto prices
More
